



RYBREVANT Faspro™

(amivantamab and hyaluronidase-Ipuj)

Subcutaneous injection | 1,600 mg/20,000 units | 2,240 mg/28,000 units



LAZCLUZE®

(lazertinib)

Tablets | 240 mg/80 mg

Administration and Management Guide

Your guide to starting and keeping your patients on treatment with RYBREVANT FASPRO™-based regimens

INDICATIONS

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-Ipuj) and RYBREVANT® (amivantamab-vmjw) are indicated:

- in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
- in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.
- in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
- as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum-based chemotherapy.

SELECT IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

RYBREVANT FASPRO™ is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.

WARNINGS AND PRECAUTIONS for RYBREVANT® and RYBREVANT FASPRO™ include: IRRs (RYBREVANT®), Hypersensitivity & ARRs (RYBREVANT FASPRO™), ILD/Pneumonitis, VTE, Dermatologic Adverse Reactions, Ocular Toxicity and Embryo-Fetal Toxicity.

Please see full Important Safety Information. Please read full
Prescribing Information for RYBREVANT FASPRO™, RYBREVANT®, and LAZCLUZE®.

[References](#) | [Important Safety Information](#) | [1](#)

OVERVIEW

PREPARATION &
ADMINISTRATION

RYBREVANT FASPRO™
+ LAZCLUZE®

RYBREVANT FASPRO™
+ CHEMOTHERAPY

RYBREVANT FASPRO™
AS A SINGLE AGENT

MONITORING &
MANAGING ARs

Table of contents

Overview	3
Preparation & Administration	4
Premedications for RYBREVANT FASPRO™	5
Prophylactic and concomitant medications	6
Proactive therapy management protocol	7
Administering RYBREVANT FASPRO™	8
Administering RYBREVANT FASPRO™ with LAZCLUZE®	9
RYBREVANT FASPRO™ + LAZCLUZE®	10
RYBREVANT FASPRO™ + Chemotherapy (carboplatin/pemetrexed)	12
RYBREVANT FASPRO™ as a Single Agent	14
Monitoring & Managing Adverse Reactions	15
Patient Counseling Information	21

Reach out to an Oncology Clinical Educator (OCE) at www.RYBREVANThcp.com/contact-a-representative. OCEs are oncology nurses employed by Johnson & Johnson to provide product-specific and disease state education information to oncology patient-care team members, patient support groups, and advocacy organizations

Please see full **Important Safety Information**. Please read full Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [2](#)

Overview¹

Premedications

Administer antihistamine, antipyretic, and glucocorticoids*:
 15 to 90 minutes prior to each injection according to the recommended premedications.

*Glucocorticoid administration is required for week 1, day 1 only and upon reinitiation after prolonged dose interruptions, then as necessary for subsequent injections.

[Learn more >](#)

Rapid injection[†]



[†]Administration time only; actual clinic time may vary.

[See details >](#)


Proactive medications

To help reduce the risk of select ARs

- **Dermatologic AR prophylaxis:**
 - Oral/topical antibiotics and ceramide-based moisturizer
 - Advise patients to limit direct sun exposure[‡]
- **VTE concomitant medications (when combined with LAZCLUZE®):**
 Anticoagulant prophylaxis for the first 4 months of treatment

[‡]During and for 2 months after treatment.

[See details >](#)



Patients currently receiving RYBREVANT® (amivantamab-vmjw) may switch to RYBREVANT FASPRO™

AR, adverse reaction; VTE, venous thromboembolism.

Please see full [Important Safety Information](#). Please read full Prescribing Information for **RYBREVANT FASPRO™**, **RYBREVANT®**, and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | 3

Preparation & storage¹

STEP 1
 Remove from
 fridge



Remove the appropriate number of RYBREVANT FASPRO™ vials from refrigerated storage

- During preparation and prior to administration, check the vial labels to ensure that the drug being prepared and administered is subcutaneous RYBREVANT FASPRO™ and not RYBREVANT® (amivantamab-vmjw)
- Do not substitute RYBREVANT FASPRO™ for or with RYBREVANT®

STEP 2
 Bring to
 room
 temp



Wait at least 15 minutes to allow vial(s) to reach room temperature

- Do not warm any other way. Do not shake or dilute

STEP 3
 Inspect
 visually



Once room temperature, inspect visually for particulate matter and discoloration prior to administration

- RYBREVANT FASPRO™ is a clear to opalescent and colorless to pale yellow solution
- Do not use if the solution is discolored or cloudy, or if foreign particles are present

STEP 4
 Withdraw
 dose



Withdraw the required injection volume from the vial(s) into a syringe(s) using a transfer needle

- RYBREVANT FASPRO™ is compatible with stainless steel injection needles, PP and PC syringes, and PE, PU, and PVC subcutaneous infusion sets. Administer using a 21G to 23G needle or infusion set to ensure ease of administration
- Each injection volume should not exceed 15 mL. Divide doses requiring greater than 15 mL into approximately equal volumes in 2 syringes

PC, polycarbonate; PE, polyethylene; PP, polypropylene; PU, polyurethane; PVC, polyvinyl chloride.

Please see full Important Safety Information. Please read full
 Prescribing Information for RYBREVANT FASPRO™ and LAZCLUZE®.

[References](#)

[Important Safety Information](#)

4

OVERVIEW

PREPARATION &
 ADMINISTRATION

RYBREVANT FASPRO™
 + LAZCLUZE®

RYBREVANT FASPRO™
 + CHEMOTHERAPY

RYBREVANT FASPRO™
 AS A SINGLE AGENT

MONITORING &
 MANAGING ARs

Premedications for RYBREVANT FASPRO™¹

ARR management

Medication	Dose	Administration		Frequency
Antihistamine	Diphenhydramine (25–50 mg) or equivalent	IV 15–30 minutes prior	OR Oral 30–60 minutes prior	All doses
Antipyretic	Acetaminophen (650–1,000 mg) or equivalent	IV 15–30 minutes prior	OR Oral 30–60 minutes prior	All doses
Glucocorticoid	Dexamethasone (20 mg) or equivalent	IV 45–60 minutes prior	OR Oral At least 60 minutes prior	Initial dose (week 1, day 1)*
Glucocorticoid (optional)	Dexamethasone (10 mg) or equivalent	IV 45–60 minutes prior	OR Oral 60–90 minutes prior	Optional for subsequent doses

RYBREVANT FASPRO™ observation time: 89% of ARRs in PALOMA-3 occurred on week 1, day 1, and median onset time of ARRs was ~2 hours. Monitor patients for any signs and symptoms of ARRs during injection in a setting where cardiopulmonary resuscitation medication and equipment are available. Patient monitoring time is up to healthcare provider discretion.

*Glucocorticoid administration is also required after prolonged dose interruptions, then as necessary for subsequent injections.

ARR, administration-related reaction; IV, intravenous.

Please see full **Important Safety Information**. Please read full Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [5](#)

Prophylactic and concomitant medications¹

Dermatologic AR prophylaxis

Prophylactic measures (eg, use of oral/topical antibiotics) are recommended to reduce the risk of dermatologic ARs. When initiating treatment with RYBREVANT FASPRO™, ceramide-based moisturizer is recommended.

VTE concomitant medications

When initiating treatment with RYBREVANT FASPRO™ in combination with LAZCLUZE®, implement anticoagulant prophylaxis to reduce the risk of VTE events for the first 4 months of treatment.

- The use of vitamin K antagonists is not recommended
- If there are no signs or symptoms of VTE during the first 4 months of treatment, consider discontinuation of anticoagulant prophylaxis at the discretion of the healthcare provider

Refer to the full [Prescribing Information](#) for LAZCLUZE® for information about concomitant medications.

See the next page for additional information on prophylaxis

Proactive strategies that may help patients start and stay on RYBREVANT FASPRO™ + LAZCLUZE®

ARR premedications ¹	Glucocorticoid prior to initial injection (week 1, day 1)*	Antihistamine and antipyretic prior to each injection							Learn more about the importance of proactive therapy management to help optimize outcomes
		Month	1	2	3	4	5	6	
At-home treatment protocol			VTE prophylaxis ¹⁻³						
			Months 1–4: Anticoagulation (eg, DOACs or LMWHs) [†]						
			COCOON dermatologic prophylaxis ^{1,2}						
			Months 1–3: Doxycycline or minocycline 100 mg twice daily		Months 4–12: Topical clindamycin 1% lotion on the scalp before bedtime				
			Daily: Ceramide-based moisturizer on the body and face at least once daily						
			Daily: Wear protective clothing and broad-spectrum sunscreen (SPF ≥30)						
			Daily: Chlorhexidine 4% wash on fingernails and toenails for paronychia						

Month = month of treatment with RYBREVANT FASPRO™ and LAZCLUZE®.

*Required at initial dose (week 1, day 1) and after prolonged dose interruptions, then as necessary for subsequent injections.¹

[†]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for cancer-associated VTE disease: anticoagulant options for VTE prophylaxis for ambulatory patients with cancer include DOACs and LMWHs.^{3‡}

[‡]Recommendations derived from clinical trials of ambulatory patients with cancer with high thrombosis risk (>18 years, Khorana VTE Risk Score of ≥2, initiating new course of chemotherapy) and are not included in product labeling. Prophylaxis duration should be 6 months or longer if risk persists.³

DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin; NCCN, National Comprehensive Cancer Network; SPF, sun protection factor.

Please see full **Important Safety Information**. Please read full Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [7](#)


Administering subcutaneous RYBREVANT FASPRO™¹

Administer premedications before each RYBREVANT FASPRO™ dose as recommended to reduce the risk of ARRs.




RYBREVANT FASPRO™ is for subcutaneous use only. Do not administer RYBREVANT FASPRO™ intravenously

Once the syringe(s) are prepped, prepare to administer the injection. RYBREVANT FASPRO™ must be administered by a healthcare professional



- Inject the required volume of RYBREVANT FASPRO™ into the subcutaneous tissue of the abdomen over approximately 5 minutes to minimize injection site irritation



- If the total dose requires multiple injections of RYBREVANT FASPRO™, administer each injection consecutively in separate quadrants of the abdomen, with each injection taking approximately 5 minutes

- Do not inject into tattoos or scars or areas where the skin is red, bruised, tender, hard, not intact, or within 2 inches (5 cm) around the periumbilical area
- If the patient experiences pain, pause or slow down delivery
 - If the pain is not alleviated by pausing or slowing down the delivery rate, deliver the rest of the dose in a second injection site on the opposite side of the abdomen
- If administering with a subcutaneous infusion set, ensure the full dose is delivered through the infusion set. A 0.9% sodium chloride solution may be used to flush the remaining liquid through the line
- Discard unused portion

Please see full **Important Safety Information**. Please read full Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [8](#)

Administering subcutaneous RYBREVANT FASPRO™ with LAZCLUZE®⁴

 When given in combination with LAZCLUZE®, administer RYBREVANT FASPRO™ any time after LAZCLUZE® when given on the same day

- ✓ Administer LAZCLUZE® 240 mg orally once daily
- ✓ Swallow LAZCLUZE® tablets whole (with or without food). Do not crush, split, or chew
- ✓ If a patient misses a dose of LAZCLUZE® within 12 hours, instruct the patient to take the missed dose. If more than 12 hours have passed since the dose was to be given, instruct the patient to take the next dose at its scheduled time
- ✓ If vomiting occurs any time after taking LAZCLUZE®, instruct the patient to take the next dose at its next regularly scheduled time

Drug interactions with LAZCLUZE®


- ✗ Avoid concomitant use of LAZCLUZE® with strong and moderate CYP3A4 inducers. Consider an alternate concomitant medication with no potential to induce CYP3A4
- ✓ Monitor for adverse reactions associated with a CYP3A4 or BCRP substrate where minimal concentration changes may lead to serious adverse reactions, as recommended in the approved product labeling for the CYP3A4 or BCRP substrate

BCRP, breast cancer resistance protein; CYP3A4, cytochrome P450 3A4.

Please see full [Important Safety Information](#). Please read full
[Prescribing Information for RYBREVANT FASPRO™ and LAZCLUZE®](#).

[References](#) | [Important Safety Information](#) | 9

Recommended dosing schedule for RYBREVANT FASPRO™ + LAZCLUZE® (Q2W)^{1,4}



RYBREVANT FASPRO™

The recommended dosage of RYBREVANT FASPRO™ is based on baseline body weight and administered as a subcutaneous injection. Please see the full [Prescribing Information](#) for RYBREVANT FASPRO™ for units of hyaluronidase for each dose and for any additional dosage and administration guidance.¹

Contraindications

RYBREVANT FASPRO™ is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.¹

With LAZCLUZE®

Administer RYBREVANT FASPRO™ any time after LAZCLUZE® when given on the same day. Refer to the full [Prescribing Information](#) for LAZCLUZE® for recommended LAZCLUZE® dosage and administration information.¹

If switching from RYBREVANT® (amivantamab-vmjw) Q2W dosing to RYBREVANT FASPRO™ Q2W dosing, switch patients at their next scheduled dose on or after week 5.¹

*Dose adjustments not required for subsequent body weight changes.¹
 Q2W, every 2 weeks.

Please see full [Important Safety Information](#). Please read full Prescribing Information for RYBREVANT FASPRO™, RYBREVANT®, and LAZCLUZE®.

[References](#) | [Important Safety Information](#) | [10](#)

Next: Recommended dosing schedule for RYBREVANT FASPRO™ + chemotherapy (Q3W)

RYBREVANT FASPRO™ + LAZCLUZE® (Q2W) vial selection and dose volume¹

Vial selection and dose volume

STEP 1

Select the right vial for the starting dose based on patient weight at baseline



STEP 2

Determine dose volume needed



1,600 mg amivantamab



ONE 10 mL VIAL
1,600 mg amivantamab/10 mL vial



Administer 10 mL



2,240 mg amivantamab



ONE 14 mL VIAL
2,240 mg amivantamab/14 mL vial




Administer 14 mL

Please see the [Prescribing Information](#) for RYBREVANT FASPRO™ for units of hyaluronidase for each dose.

Please see full [Important Safety Information](#). Please read full Prescribing Information for RYBREVANT FASPRO™ and LAZCLUZE®.

[References](#) | [Important Safety Information](#) | [11](#)

Recommended dosing schedule for RYBREVANT FASPRO™ + chemotherapy (Q3W)¹



RYBREVANT FASPRO™

The recommended dosage of RYBREVANT FASPRO™ is based on baseline body weight and administered as a subcutaneous injection. Please see the full [Prescribing Information](#) for RYBREVANT FASPRO™ for units of hyaluronidase for each dose.

Contraindications

RYBREVANT FASPRO™ is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.

With chemotherapy

Administer RYBREVANT FASPRO™ after chemotherapy. Administer in the following order: pemetrexed, carboplatin, and then RYBREVANT FASPRO™. Refer to the full Prescribing Information for pemetrexed and carboplatin for the respective dosing information.

If switching from RYBREVANT® (amivantamab-vmjw) Q3W dosing to RYBREVANT FASPRO™ Q3W dosing, switch patients at their next scheduled dose on or after week 4.

*Dose adjustments not required for subsequent body weight changes.

[†]Divide doses requiring greater than 15 mL into approximately equal volumes in 2 syringes and administer at separate injection sites. Each injection volume should not exceed 15 mL. Discard unused portion.

[‡]This refers only to RYBREVANT FASPRO™ and pemetrexed. Carboplatin should only be administered every 3 weeks for up to 12 weeks.

AUC, area under the curve; Q3W, every 3 weeks.

Please see full [Important Safety Information](#). Please read full

Prescribing Information for **RYBREVANT FASPRO™**, **RYBREVANT®**, and **LAZCLUZE®**.

[References](#)

[Important Safety Information](#)

12

RYBREVANT FASPRO™ + chemotherapy (Q3W) vial selection and dose volume¹


STEP 1

Select the right vial for the starting dose based on patient weight at baseline



STEP 2

Determine dose volume needed



STARTING DOSE
1,600 mg amivantamab/10 mL



ONE 10 mL VIAL
1,600 mg amivantamab/10 mL vial

Administer 10 mL

SUBSEQUENT DOSES
2,400 mg amivantamab/15 mL*



TWO 10 mL VIALS
1,600 mg amivantamab/10 mL vial



Administer 15 mL*

STARTING DOSE
2,240 mg amivantamab/14 mL



ONE 14 mL VIAL
2,240 mg amivantamab/14 mL vial

Administer 14 mL

SUBSEQUENT DOSES
3,360 mg amivantamab/21 mL†



ONE 14 mL VIAL
2,240 mg amivantamab/
14 mL vial

ONE 10 mL VIAL
1,600 mg amivantamab/
10 mL vial



Administer 21 mL*†

Please see the [Prescribing Information](#) for RYBREVANT FASPRO™ for units of hyaluronidase for each dose.

*The entire contents of all vials will not be needed. Discard unused portion.

†Divide the 21 mL dose volume approximately equally into 2 syringes (each syringe should not exceed 15 mL).

Please see full [Important Safety Information](#). Please read full
Prescribing Information for RYBREVANT FASPRO™ and LAZCLUZE®.


Recommended dosing for RYBREVANT FASPRO™ as a single agent¹



The recommended dosage is based on baseline body weight and administered as a subcutaneous injection. Please see the [Prescribing Information](#) for RYBREVANT FASPRO™ for units of hyaluronidase for each dose.

If switching from RYBREVANT® (amivantamab-vmjw) Q2W dosing to RYBREVANT FASPRO™ Q2W dosing, switch patients at their next scheduled dose on or after week 5.

Vial selection and dose volume



*Dose adjustments not required for subsequent body weight changes.

Please see full [Important Safety Information](#). Please read full [Prescribing Information](#) for RYBREVANT FASPRO™, RYBREVANT®, and LAZCLUZE®.

[References](#) | [Important Safety Information](#) | [14](#)

Monitoring & managing ARs

Guide patients toward their goals with their optimal dose^{1,4}

Dose modification steps to consider:



INITIATE
prophylactic strategies



PAUSE



REDUCE



REEVALUATE

Based on severity and/or recurrence, certain ARs require discontinuation.¹ See specific guidance for dose modifications on the next pages.

Note: If a dose modification is needed for RYBREVANT FASPRO™, treatment may be continued with LAZCLUZE®.^{1,4}

Please see full Important Safety Information. Please read full Prescribing Information for RYBREVANT FASPRO™ and LAZCLUZE®.

[References](#) | [Important Safety Information](#) | [15](#)

Monitoring & managing ARs (cont'd)

Recommended RYBREVANT FASPRO™ dose reductions for ARs¹

Table continues on next page

Dose reductions for ARs			
Dose at which the AR occurred	1st dose reduction	2nd dose reduction	3rd dose reduction
1,600 mg amivantamab	1,050 mg amivantamab*	700 mg amivantamab [†]	
2,240 mg amivantamab	1,600 mg amivantamab [‡]	1,050 mg amivantamab*	
2,400 mg amivantamab	1,600 mg amivantamab [‡]	1,050 mg amivantamab*	Discontinue RYBREVANT FASPRO™
3,360 mg amivantamab	2,240 mg amivantamab [§]	1,600 mg amivantamab [‡]	

Please see the [Prescribing Information](#) for RYBREVANT FASPRO™ for units of hyaluronidase for each dose.

Recommended LAZCLUZE® dose reductions for ARs⁴

Dose reductions for ARs			
Dose at which the AR occurred	1st dose reduction	2nd dose reduction	3rd dose reduction
240 mg once daily (one 240 mg tablet)	160 mg once daily (two 80 mg tablets)	80 mg once daily (one 80 mg tablet)	Discontinue LAZCLUZE®

*The dose volume should be 6.6 mL for 1,050 mg amivantamab and 13,200 units hyaluronidase.¹

[†]The dose volume should be 4.4 mL for 700 mg amivantamab and 8,800 units hyaluronidase.¹

[‡]The dose volume should be 10 mL for 1,600 mg amivantamab and 20,000 units hyaluronidase.¹

[§]The dose volume should be 14 mL for 2,240 mg amivantamab and 28,000 units hyaluronidase.¹

Please see full [Important Safety Information](#). Please read full
 Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [16](#)

Monitoring & managing ARs (cont'd)

Adverse event severity scale⁵

Based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0*

Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated	Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) [†]	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL [‡]	Life-threatening consequences; urgent intervention indicated	Death related to adverse event

Recommended dosage modifications and management for ARs for RYBREVANT FASPRO™ + LAZCLUZE®^{1,4}

For RYBREVANT FASPRO™ + LAZCLUZE®, refer to both the RYBREVANT FASPRO™ and LAZCLUZE® recommendations. For RYBREVANT FASPRO™ + chemotherapy or RYBREVANT FASPRO™ as a single agent, refer only to the RYBREVANT FASPRO™ recommendations.

VTE Events (applies to RYBREVANT FASPRO™ + LAZCLUZE® combination only)

Table continues on next page

Severity	Dosage modifications		
Grade 2 or 3	Withhold Withhold both drugs	Administer Administer anticoagulant treatment as clinically indicated	Resume Once anticoagulant treatment has been initiated, resume both drugs at the same dose level, at the discretion of the treating physician
Grade 4 or recurrent grade 2 or 3 despite therapeutic level anticoagulation	Discontinue Discontinue RYBREVANT FASPRO™ permanently Withhold Withhold LAZCLUZE®	Administer Administer anticoagulant treatment as clinically indicated	Resume Once anticoagulant treatment has been initiated, treatment can continue with LAZCLUZE® at the same dose level, at the discretion of the treating physician

*CTCAE definition may differ from the Prescribing Information.

[†]Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

[‡]Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not being bedridden.

Please see full **Important Safety Information**. Please read full Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [17](#)

Monitoring & managing ARs (cont'd)

Recommended dosage modifications and management for ARs for RYBREVANT FASPRO™ + LAZCLUZE®^{1,4}

For RYBREVANT FASPRO™ + LAZCLUZE®, refer to **both** the RYBREVANT FASPRO™ and LAZCLUZE® recommendations. For RYBREVANT FASPRO™ + chemotherapy or RYBREVANT FASPRO™ as a single agent, refer only to the RYBREVANT FASPRO™ recommendations.



Hypersensitivity and Administration-Related Reactions

Table continues on next page

Severity	Dosage modifications		
Grade 1 or 2	<p>Interrupt Interrupt RYBREVANT FASPRO™ injection if ARR is suspected and monitor patient until reaction symptoms resolve</p>	<p>Resume Resume injection upon resolution of symptoms</p>	<p>Include prophylaxis Include corticosteroid with premedications for subsequent dose of RYBREVANT FASPRO™</p>
Grade 3	<p>Interrupt Interrupt RYBREVANT FASPRO™ injection and administer supportive care medications. Continuously monitor patient until reaction symptoms resolve</p>	<p>Resume Resume injection upon resolution of symptoms</p>	<p>Include prophylaxis Include corticosteroid with premedications for subsequent dose of RYBREVANT FASPRO™</p> <p>Discontinue For recurrent grade 3, discontinue RYBREVANT FASPRO™ permanently</p>
Grade 4	<p>Discontinue Discontinue RYBREVANT FASPRO™ permanently</p>		



ILD/Pneumonitis

Severity	Dosage modifications	
Any grade	<p>Withhold Withhold both drugs if suspected</p>	<p>Discontinue Discontinue both drugs permanently if confirmed</p>

ILD, interstitial lung disease.

Please see full **Important Safety Information**. Please read full Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [18](#)

Monitoring & managing ARs (cont'd)

Recommended dosage modifications and management for ARs for RYBREVANT FASPRO™ + LAZCLUZE®^{1,4}

For RYBREVANT FASPRO™ + LAZCLUZE®, refer to **both** the RYBREVANT FASPRO™ and LAZCLUZE® recommendations. For RYBREVANT FASPRO™ + chemotherapy or RYBREVANT FASPRO™ as a single agent, refer only to the RYBREVANT FASPRO™ recommendations.

Dermatologic ARs (including dermatitis acneiform, pruritus, dry skin)

Table continues on next page

Severity	Dosage modifications			
Grade 1	Initiate Initiate supportive care management as clinically indicated	Reassess Reassess after 2 weeks; if rash does not improve, consider dose reduction of RYBREVANT FASPRO™		
Grade 2	Initiate Initiate supportive care management as clinically indicated	Reassess Reassess after 2 weeks; if rash does not improve, reduce RYBREVANT FASPRO™ dose and continue LAZCLUZE® at the same dose	Reassess Reassess every 2 weeks; if no improvement, reduce LAZCLUZE® dose until grade ≤1, then may resume previous dose of LAZCLUZE® at the discretion of the healthcare provider	
Grade 3	Withhold Withhold both drugs and initiate supportive care management as clinically indicated	Reassess Upon recovery to grade ≤2, resume RYBREVANT FASPRO™ at a reduced dose; resume LAZCLUZE® at the same dose or consider dose reduction	Discontinue If there is no improvement within 2 weeks, discontinue both drugs permanently	
Grade 4 (including severe bullous, blistering, or exfoliating skin conditions, including TEN for RYBREVANT FASPRO™)	Discontinue Discontinue RYBREVANT FASPRO™ permanently	Initiate Initiate supportive care management as clinically indicated	Withhold Withhold LAZCLUZE® until recovery to grade ≤2 or baseline	Resume Upon recovery to grade ≤2, resume LAZCLUZE® at a reduced dose at the discretion of the healthcare provider

TEN, toxic epidermal necrolysis.

Please see full **Important Safety Information**. Please read full Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [19](#)

Monitoring & managing ARs (cont'd)

Recommended dosage modifications and management for ARs for RYBREVANT FASPRO™ + LAZCLUZE®^{1,4}

For RYBREVANT FASPRO™ + LAZCLUZE®, refer to **both** the RYBREVANT FASPRO™ and LAZCLUZE® recommendations. For RYBREVANT FASPRO™ + chemotherapy or RYBREVANT FASPRO™ as a single agent, refer only to the RYBREVANT FASPRO™ recommendations.

Other ARs

Severity	Dosage modifications		
Grade 3	Withhold Withhold both drugs until recovery to grade ≤1 or baseline	Resume Resume both drugs at the same dose if recovery occurs within 1 week Resume both drugs at reduced dose or LAZCLUZE® alone if recovery occurs after 1 week but within 4 weeks	Discontinue Discontinue both drugs permanently if recovery does not occur within 4 weeks
Grade 4	Withhold Withhold both drugs until recovery to grade ≤1 or baseline	Resume Resume both drugs at reduced dose or LAZCLUZE® alone if recovery occurs within 4 weeks	Discontinue Discontinue both drugs permanently if recovery does not occur within 4 weeks Discontinue RYBREVANT FASPRO™ permanently for recurrent grade 4 reactions

Recommended dosage modifications for ARs for RYBREVANT FASPRO™ in combination with LAZCLUZE®¹

When administering RYBREVANT FASPRO™ in combination with LAZCLUZE®, if there is an AR requiring dose reduction after withholding treatment and resolution, reduce the dose of RYBREVANT FASPRO™ first.

Recommended dosage modifications for ARs for RYBREVANT FASPRO™ in combination with carboplatin and pemetrexed¹

When administering RYBREVANT FASPRO™ in combination with carboplatin and pemetrexed, modify the dosage of one or more drugs. Withhold or discontinue RYBREVANT FASPRO™ as shown in the tables on pages 17-20. Refer to the Prescribing Information for carboplatin and pemetrexed for additional dosage modification information.

Please see full [Important Safety Information](#). Please read full [Prescribing Information for RYBREVANT FASPRO™ and LAZCLUZE®](#).

[References](#) | [Important Safety Information](#) | [20](#)

Patient counseling information

Advise the patient to read the FDA-approved patient labeling (Patient Information)

Hypersensitivity and ARRs^{1,4}	RYBREVANT FASPRO™ can cause hypersensitivity and administration-related reactions, the majority of which may occur with the first injection. Advise patients to alert their healthcare provider immediately for any signs or symptoms of administration-related reactions during treatment with RYBREVANT FASPRO™.
ILD/pneumonitis^{1,4}	RYBREVANT FASPRO™ can cause interstitial lung disease (ILD)/pneumonitis. Advise patients to immediately contact their healthcare provider for new or worsening respiratory symptoms during treatment with RYBREVANT FASPRO™.
VTE events with concomitant use with LAZCLUZE®^{1,4}	When RYBREVANT FASPRO™ is used in combination with LAZCLUZE®, it can cause serious and life-threatening venous thromboembolic events (VTE), including deep venous thrombosis and pulmonary embolism. Advise patients that prophylactic anticoagulants are recommended to be used for the first four months of treatment. Advise patients to immediately contact their healthcare provider for signs and symptoms of VTE during treatment with RYBREVANT FASPRO™.
Dermatologic ARs^{1,4}	RYBREVANT FASPRO™ can cause dermatologic adverse reactions. Advise patients that prophylactic oral antibiotics are recommended starting on day 1 for the first 12 weeks of treatment and, after completion of oral antibiotic treatment, topical antibiotic lotion to the scalp for the next 9 months of treatment. Advise patients to use a non-comedogenic skin moisturizer (ceramide-based or other formulations that provide long-lasting skin hydration and exclude drying components) on the face and whole body (except scalp) and 4% chlorhexidine solution to wash hands and feet, while on treatment. Advise patients to limit direct sun exposure during and for 2 months after treatment, to wear protective clothing, and to use broad-spectrum UVA/UVB sunscreen to reduce the risk and severity of dermatologic adverse reactions.
Ocular toxicity^{1,4}	RYBREVANT FASPRO™ can cause ocular toxicity. Advise patients to contact their ophthalmologist if they develop eye symptoms and advise discontinuation of contact lenses until symptoms are evaluated.
Paronychia/nail toxicity^{1,4}	RYBREVANT FASPRO™ can cause paronychia. Advise patients to contact their healthcare provider for signs or symptoms of paronychia.
Embryo-fetal toxicity^{1,4}	Advise females of reproductive potential of the potential risk to a fetus, to use effective contraception during treatment with RYBREVANT FASPRO™ and for 3 months after the last dose, and to inform their healthcare provider of a known or suspected pregnancy.
Lactation^{1,4}	Advise women not to breastfeed during treatment with RYBREVANT FASPRO™ and for 3 months after the last dose.
Infertility⁴	Advise males and females of reproductive potential of the potential risk for impaired fertility with LAZCLUZE®.

UVA, ultraviolet A; UVB, ultraviolet B.

Please see full **Important Safety Information**. Please read full Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [21](#)

References

References: 1. RYBREVANT FASPRO™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Cho BC, Li W, Spira AI, et al. Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial. *J Thorac Oncol.* 2025;20(10):1517-1530. doi:10.1016/j.jtho.2025.07.117 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cancer-Associated Venous Thromboembolic Disease V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 6, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. LAZCLUZE® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 5. US Department of Health and Human Services. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0. Published November 27, 2017. Accessed December 10, 2025. <https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf>

Please see full [Important Safety Information](#). Please read full Prescribing Information for **RYBREVANT FASPRO™** and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [22](#)

Indications and Important Safety Information

INDICATIONS

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-ipuj) and RYBREVANT® (amivantamab-vmjw) are indicated:

- in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
- in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.
- in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
- as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum-based chemotherapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

RYBREVANT FASPRO™ is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity and Administration-Related Reactions with RYBREVANT FASPRO™

RYBREVANT FASPRO™ can cause hypersensitivity and administration-related reactions (ARR); signs and symptoms of ARR include dyspnea, flushing, fever, chills, chest discomfort, hypotension, and vomiting. The median time to ARR onset is approximately 2 hours.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), all Grade ARR occurred in 13% of patients, including 0.5% Grade 3. Of the patients who experienced ARR, 89% occurred with the initial dose (Week 1, Day 1).

Please see full Important Safety Information. Please read full

Prescribing Information for RYBREVANT FASPRO™, RYBREVANT®, and LAZCLUZE®.

[References](#) | [Important Safety Information](#) | [23](#)

Important Safety Information (cont'd)

Premedicate with antihistamines, antipyretics, and glucocorticoids and administer RYBREVANT FASPRO™ as recommended. Monitor patients for any signs and symptoms of administration-related reactions during injection in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt RYBREVANT FASPRO™ injection if ARR is suspected. Resume treatment upon resolution of symptoms or permanently discontinue RYBREVANT FASPRO™ based on severity.

Infusion-Related Reactions with RYBREVANT®

RYBREVANT® can cause infusion-related reactions (IRR) including anaphylaxis; signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. The median time to IRR onset is approximately 1 hour.

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), IRRs occurred in 63% of patients, including Grade 3 in 5% and Grade 4 in 1% of patients. IRR-related infusion modifications occurred in 54%, dose reduction in 0.7%, and permanent discontinuation of RYBREVANT® in 4.5% of patients.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population (n=281), IRRs occurred in 50% of patients including Grade 3 (3.2%) adverse reactions. IRR-related infusion modifications occurred in 46%, and permanent discontinuation of RYBREVANT® in 2.8% of patients.

RYBREVANT® as a Single Agent

In CHRYSALIS (n=302), IRRs occurred in 66% of patients. IRRs occurred in 65% of patients on Week 1 Day 1, 3.4% on Day 2 infusion, 0.4% with Week 2 infusion, and were cumulatively 1.1% with subsequent infusions. 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range: 0.1 to 18 hours) after start of infusion. IRR-related infusion modifications occurred in 62%, and permanent discontinuation of RYBREVANT® in 1.3% of patients.

Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT® as recommended. Administer RYBREVANT® via a peripheral line on Week 1 and Week 2 to reduce the risk of IRRs. Monitor patients for signs and symptoms of IRRs in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT® based on severity. If an anaphylactic reaction occurs, permanently discontinue RYBREVANT®.

Interstitial Lung Disease/Pneumonitis

RYBREVANT FASPRO™ and RYBREVANT® can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.

Please see full [Important Safety Information](#). Please read full Prescribing Information for RYBREVANT FASPRO™, RYBREVANT® (amivantamab-vmjw), and [LAZCLUZE®](#).

[References](#) | [Important Safety Information](#) | [24](#)

Important Safety Information (cont'd)

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, ILD/pneumonitis occurred in 6% of patients, including Grade 3 in 1%, Grade 4 in 1.5%, and fatal cases in 1.9% of patients. 5% of patients permanently discontinued RYBREVANT FASPRO™ and LAZCLUZE® due to ILD/pneumonitis.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, ILD/pneumonitis occurred in 3.1% of patients, including Grade 3 in 1.0% and Grade 4 in 0.2% of patients. There was one fatal case of ILD/pneumonitis and 2.9% of patients permanently discontinued RYBREVANT® and LAZCLUZE® due to ILD/pneumonitis.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, ILD/pneumonitis occurred in 2.1% of patients with 1.8% of patients experiencing Grade 3 ILD/pneumonitis. 2.1% discontinued RYBREVANT® due to ILD/pneumonitis.

RYBREVANT® as a Single Agent

In CHRYSALIS, ILD/pneumonitis occurred in 3.3% of patients, with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) permanently discontinued RYBREVANT® due to ILD/pneumonitis.

Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® (when applicable) in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed.

Venous Thromboembolic (VTE) Events with Concomitant Use with LAZCLUZE®

RYBREVANT FASPRO™ and RYBREVANT® in combination with LAZCLUZE® can cause serious and fatal venous thromboembolic (VTE) events, including deep vein thrombosis and pulmonary embolism. Without prophylactic anticoagulation, the majority of these events occurred during the first four months of treatment.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), all Grade VTE occurred in 11% of patients and 1.5% were Grade 3. 80% (n=164) of patients received prophylactic anticoagulation at study entry, with an all Grade VTE incidence of 7%. In patients who did not receive prophylactic anticoagulation (n=42), all Grade VTE occurred in 17% of patients. In total, 0.5% of patients had VTE leading to dose reductions of RYBREVANT FASPRO™ and no patients required permanent discontinuation. The median time to onset of VTEs was 95 days (range: 17 to 390).

Please see full [Important Safety Information](#). Please read full Prescribing Information for **RYBREVANT FASPRO™**, **RYBREVANT®** (amivantamab-vmjw), and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [25](#)

Important Safety Information (cont'd)

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), VTEs occurred in 36% of patients including Grade 3 in 10% and Grade 4 in 0.5% of patients. On-study VTEs occurred in 1.2% of patients (n=5) while receiving anticoagulation therapy. There were two fatal cases of VTE (0.5%), 9% of patients had VTE leading to dose interruptions of RYBREVANT®, and 7% of patients had VTE leading to dose interruptions of LAZCLUZE®; 1% of patients had VTE leading to dose reductions of RYBREVANT®, and 0.5% of patients had VTE leading to dose reductions of LAZCLUZE®; 3.1% of patients had VTE leading to permanent discontinuation of RYBREVANT®, and 1.9% of patients had VTE leading to permanent discontinuation of LAZCLUZE®. The median time to onset of VTEs was 84 days (range: 6 to 777).

Administer prophylactic anticoagulation for the first four months of treatment. The use of Vitamin K antagonists is not recommended.

Monitor for signs and symptoms of VTE events and treat as medically appropriate. Withhold RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® based on severity. Once anticoagulant treatment has been initiated, resume RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® at the same dose level at the discretion of the healthcare provider. In the event of VTE recurrence despite therapeutic anticoagulation, permanently discontinue RYBREVANT FASPRO™ or RYBREVANT®. Treatment can continue with LAZCLUZE® at the same dose level at the discretion of the healthcare provider. Refer to the LAZCLUZE® Prescribing Information for recommended LAZCLUZE® dosage modification.

Dermatologic Adverse Reactions

RYBREVANT FASPRO™ and RYBREVANT® can cause severe rash including toxic epidermal necrolysis (TEN), dermatitis acneiform, pruritus and dry skin.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, rash occurred in 80% of patients, including Grade 3 in 17% and Grade 4 in 0.5% of patients. Rash leading to dose reduction occurred in 11% of patients, and RYBREVANT FASPRO™ was permanently discontinued due to rash in 1.5% of patients.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, rash occurred in 86% of patients, including Grade 3 in 26% of patients. The median time to onset of rash was 14 days (range: 1 to 556 days). Rash leading to dose interruptions occurred in 37% of patients for RYBREVANT® and 30% for LAZCLUZE®, rash leading to dose reductions occurred in 23% of patients for RYBREVANT® and 19% for LAZCLUZE®, and rash leading to permanent discontinuation occurred in 5% of patients for RYBREVANT® and 1.7% for LAZCLUZE®.

Please see full [Important Safety Information](#). Please read full Prescribing Information for **RYBREVANT FASPRO™**, **RYBREVANT®** (amivantamab-vmjw), and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | **26**

Important Safety Information (cont'd)

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, rash occurred in 82% of patients, including Grade 3 (15%) adverse reactions. Rash leading to dose reductions occurred in 14% of patients, and 2.5% permanently discontinued RYBREVANT® and 3.1% discontinued pemetrexed.

RYBREVANT® as a Single Agent

In CHRYSLIS, rash occurred in 74% of patients, including Grade 3 in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% and permanent discontinuation due to rash occurred in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3%).

When initiating treatment with RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE®, prophylactic and concomitant medications are recommended to reduce the risk and severity of dermatologic adverse reactions. Instruct patients to limit sun exposure during and for 2 months after treatment. Advise patients to wear protective clothing and use broad spectrum UVA/UVB sunscreen.

If skin reactions develop, administer supportive care including topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. For patients receiving RYBREVANT FASPRO™ or RYBREVANT® in combination with LAZCLUZE®, withhold, reduce the dose, or permanently discontinue both drugs based on severity. For patients receiving RYBREVANT FASPRO™ or RYBREVANT® as a single agent or in combination with carboplatin and pemetrexed, withhold, dose reduce or permanently discontinue RYBREVANT FASPRO™ or RYBREVANT® based on severity.

Ocular Toxicity

RYBREVANT FASPRO™ and RYBREVANT® can cause ocular toxicity including keratitis, blepharitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, eye pruritus and uveitis.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, all Grade ocular toxicity occurred in 13% of patients, including 0.5% Grade 3.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, ocular toxicity occurred in 16%, including Grade 3 or 4 ocular toxicity in 0.7% of patients.

Please see full [Important Safety Information](#). Please read full Prescribing Information for RYBREVANT FASPRO™, RYBREVANT® (amivantamab-vmjw), and LAZCLUZE®.

[References](#) | [Important Safety Information](#) | [27](#)

Important Safety Information (cont'd)

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, ocular toxicity occurred in 16% of patients. All events were Grade 1 or 2.

RYBREVANT® as a Single Agent

In CHRYSLIS, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients. All events were Grade 1-2.

Promptly refer patients presenting with new or worsening eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT FASPRO™ or RYBREVANT® and continue LAZCLUZE® based on severity.

Embryo-Fetal Toxicity

Based on animal models, RYBREVANT FASPRO™, RYBREVANT® and LAZCLUZE® can cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating RYBREVANT FASPRO™ and RYBREVANT®. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise patients of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of RYBREVANT FASPRO™ or RYBREVANT®, and for 3 weeks after the last dose of LAZCLUZE®.

ADVERSE REACTIONS

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), the most common adverse reactions ($\geq 20\%$) were rash (80%), nail toxicity (58%), musculoskeletal pain (50%), fatigue (37%), stomatitis (36%), edema (34%), nausea (30%), diarrhea (22%), vomiting (22%), constipation (22%), decreased appetite (22%), and headache (21%). The most common Grade 3 or 4 laboratory abnormalities ($\geq 2\%$) were decreased lymphocyte count (6%), decreased sodium (5%), decreased potassium (5%), decreased albumin (4.9%), increased alanine aminotransferase (3.4%), decreased platelet count (2.4%), increased aspartate aminotransferase (2%), increased gamma-glutamyl transferase (2%), and decreased hemoglobin (2%).

Serious adverse reactions occurred in 33% of patients, with those occurring in $\geq 2\%$ of patients including ILD/pneumonitis (6%); and pneumonia, VTE and fatigue (2.4% each). Death due to adverse reactions occurred in 5% of patients treated with RYBREVANT FASPRO™, including ILD/pneumonitis (1.9%), pneumonia (1.5%), and respiratory failure and sudden death (1% each).

Please see full [Important Safety Information](#). Please read full Prescribing Information for RYBREVANT FASPRO™, RYBREVANT® (amivantamab-vmjw), and LAZCLUZE®.

[References](#) | [Important Safety Information](#) | 28

Important Safety Information (cont'd)

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), the most common adverse reactions (ARs) ($\geq 20\%$) were rash (86%), nail toxicity (71%), infusion-related reactions (IRRs) (RYBREVANT®) (63%), musculoskeletal pain (47%), stomatitis (43%), edema (43%), VTE (36%), paresthesia (35%), fatigue (32%), diarrhea (31%), constipation (29%), COVID-19 (26%), hemorrhage (25%), dry skin (25%), decreased appetite (24%), pruritus (24%), and nausea (21%). The most common Grade 3 or 4 laboratory abnormalities ($\geq 2\%$) were decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).

Serious ARs occurred in 49% of patients, with those occurring in $\geq 2\%$ of patients including VTE (11%), pneumonia (4%), ILD/pneumonitis and rash (2.9% each), COVID-19 (2.4%), and pleural effusion and IRRs (RYBREVANT®) (2.1% each). Fatal ARs occurred in 7% of patients due to death not otherwise specified (1.2%); sepsis and respiratory failure (1% each); pneumonia, myocardial infarction, and sudden death (0.7% each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).

RYBREVANT® with Carboplatin and Pemetrexed

In MARIPOSA-2 (n=130), the most common ARs ($\geq 20\%$) were rash (72%), IRRs (59%), fatigue (51%), nail toxicity (45%), nausea (45%), constipation (39%), edema (36%), stomatitis (35%), decreased appetite (31%), musculoskeletal pain (30%), vomiting (25%), and COVID-19 (21%). The most common Grade 3 to 4 laboratory abnormalities ($\geq 2\%$) were decreased neutrophils (49%), decreased white blood cells (42%), decreased lymphocytes (28%), decreased platelets (17%), decreased hemoglobin (12%), decreased potassium (11%), decreased sodium (11%), increased alanine aminotransferase (3.9%), decreased albumin (3.8%), and increased gamma-glutamyl transferase (3.1%).

In MARIPOSA-2, serious ARs occurred in 32% of patients, with those occurring in $>2\%$ of patients including dyspnea (3.1%), thrombocytopenia (3.1%), sepsis (2.3%), and PE (2.3%). Fatal ARs occurred in 2.3% of patients; these included respiratory failure, sepsis, and ventricular fibrillation (0.8% each).

In PAPILLON (n=151), the most common ARs ($\geq 20\%$) were rash (90%), nail toxicity (62%), stomatitis (43%), IRRs (42%), fatigue (42%), edema (40%), constipation (40%), decreased appetite (36%), nausea (36%), COVID-19 (24%), diarrhea (21%), and vomiting (21%). The most common Grade 3 to 4 laboratory abnormalities ($\geq 2\%$) were decreased albumin (7%), increased alanine aminotransferase (4%), increased gamma-glutamyl transferase (4%), decreased sodium (7%), decreased potassium (11%), decreased magnesium (2%), and decreases in white blood cells (17%), hemoglobin (11%), neutrophils (36%), platelets (10%), and lymphocytes (11%).

Please see full [Important Safety Information](#). Please read full Prescribing Information for **RYBREVANT FASPRO™**, **RYBREVANT®** (amivantamab-vmjw), and **LAZCLUZE®**.

[References](#) | [Important Safety Information](#) | [29](#)



Important Safety Information (cont'd)

In PAPILLON, serious ARs occurred in 37% of patients, with those occurring in $\geq 2\%$ of patients including rash, pneumonia, ILD, PE, vomiting, and COVID-19. Fatal adverse reactions occurred in 7 patients (4.6%) due to pneumonia, cerebrovascular accident, cardio-respiratory arrest, COVID-19, sepsis, and death not otherwise specified.

RYBREVANT® as a Single Agent

In CHRYSLALIS (n=129), the most common ARs ($\geq 20\%$) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade 3 to 4 laboratory abnormalities ($\geq 2\%$) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%).

Serious ARs occurred in 30% of patients, with those occurring in $\geq 2\%$ of patients including PE, pneumonitis/ILD, dyspnea, musculoskeletal pain, pneumonia, and muscular weakness. Fatal adverse reactions occurred in 2 patients (1.5%) due to pneumonia and 1 patient (0.8%) due to sudden death.

LAZCLUZE® DRUG INTERACTIONS

Avoid concomitant use of LAZCLUZE® with strong and moderate CYP3A4 inducers. Consider an alternate concomitant medication with no potential to induce CYP3A4.

Monitor for adverse reactions associated with a CYP3A4 or BCRP substrate where minimal concentration changes may lead to serious adverse reactions, as recommended in the approved product labeling for the CYP3A4 or BCRP substrate.

Please read full Prescribing Information for RYBREVANT FASPRO™, RYBREVANT® (amivantamab-vmjw), and LAZCLUZE®.

cp-491009v1

© Johnson & Johnson and its affiliates 2025 12/25 cp-531993v1

Johnson&Johnson

[References](#) | [Important Safety Information](#) | [30](#)

OVERVIEW

PREPARATION &
ADMINISTRATION

RYBREVANT FASPRO™
+ LAZCLUZE®

RYBREVANT FASPRO™
+ CHEMOTHERAPY

RYBREVANT FASPRO™
AS A SINGLE AGENT

MONITORING &
MANAGING ARs